

Oleanane triterpenes with protein
tyrosine phosphatase 1B
inhibitory activity from aerial parts
of *Lantana camara* collected in
Indonesia and Japan

by Deiske Sumilat 10


Submission date: 20-Aug-2019 10:18AM (UTC+0700)

Submission ID: 1161611038

File name: 2017_DASumilat_Oleanane.pdf (693.83K)

Word count: 6462

Character count: 27581



Oleanane triterpenes with protein tyrosine phosphatase 1B inhibitory activity from aerial parts of *Lantana camara* collected in Indonesia and Japan



Delfly B. Abdjul^{a,b}, Hiroyuki Yamazaki^{a,*}, Wilmar Maarisit^{a,c}, Henki Rotinsulu^d, Defny S. Wewengkang^e, Deiske A. Sumilat^c, Magie M. Kapojos^e, Fitje Losung^c, Kazuyo Ukai^a, Michio Namikoshi^a

^a Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Japan

^b 10th Sulawesi Research and Development Agency, 17 Agustus Street, Manado 95117, Indonesia

^c Faculty of Fisheries and Marine Science, Sam Ratulangi University, Kampus Bahu, Manado 95115, Indonesia

^d Faculty of Mathematic and Natural Sciences, Sam Ratulangi University, Kampus Bahu, Manado 95115, Indonesia

^e Faculty of Nursing, University of Pembangunan Indonesia, Bahu, Manado 95115, Indonesia

ARTICLE INFO

Article history:

Received 1 April 2017

Received in revised form

28 August 2017

Accepted 29 August 2017

Keywords:

Lantana camara L.

Verbenaceae

Oleanane triterpene

Phytochemical profile

Protein tyrosine phosphatase 1B

Inhibitor

ABSTRACT

During the search for new protein tyrosine phosphatase (PTP) 1B inhibitors, EtOH extracts from the aerial parts of *Lantana camara* L. (lantana) collected at Manado (Indonesia) and two subtropical islands in Japan (Ishigaki and Iriomote Islands, Okinawa) exhibited potent inhibitory activities against PTP1B in an enzyme assay. Four previously undescribed oleanane triterpenes were isolated together with known triterpenes and flavones from the Indonesian lantana. The EtOH extracts of lantana collected in Ishigaki and Iriomote Islands exhibited different phytochemical profiles from each other and the Indonesian lantana. Triterpenes with a 24-OH group were isolated from the Indonesian lantana only. Five known triterpene compounds were detected in the Ishigaki lantana, and two oleanane triterpenes with an ether linkage between 3 β and 25 were the 22 in components together with five known triterpenes as minor components in the Iriomote lantana. The structures of previously undescribed compounds were assigned on the basis of their spectroscopic data. Among the compounds obtained in this study, oleanolic acid exhibited the most potent activity against PTP1B, and is used as a positive control in studies on PTP1B. © 2017 Elsevier Ltd. All rights reserved.

1. Introduction

In the course of our research on protein tyrosine phosphatase (PTP) 1B inhibitors from natural resources in tropical and subtropical areas, we reported 33 w PTP1B inhibitors with various structural features (Abdjul et al., 2016; Yamazaki et al., 2016; Maarisit et al., 2017; Sumilat et al., 2017) and demonstrated that EtOH extracts from the aerial parts of *Lantana camara* L. (lantana) in Indonesia (Manado) and two subtropical islands in Japan (Ishigaki and Iriomote Islands, Okinawa) inhibited PTP1B activity.

L. camara belongs to the family Verbenaceae and is commonly known as lantana (Ghisalberti, 2000). The plant is a hairy shrub native to tropical and subtropical America and is now growing

throughout tropical, subtropical, and temperate regions. It is also cultivated as an ornamental plant. Several parts of the plant have been used as folk medicine to cure various diseases. Its leaves are used to treat scrapes and cuts in Indonesia, and a tea prepared from its leaves in Okinawa, Japan traditionally improved rheumatism (Ghisalberti, 2000). A number of phytochemical studies have been performed on *L. camara* and identified various triterpenoids as well as iridoid glycosides, furanonaphthoquinones, and flavonoids (Ghisalberti, 2000).

PTP1B is an enzyme that negatively regulates cell signaling transmitted from insulin and leptin receptors (Maheswari et al., 2017; Zhang and Zhang, 2007), and it is considered to be promising drugs for the treatment of type 2 diabetes and obesity (Wang et al., 2015).

The bioassay-guided separation of extracts gave 22 oleanane triterpenes (1–22) and three flavonoids (23–25), including four previously undescribed compounds (1–4) (Fig. 1). The structures of

* Corresponding author.

E-mail address: yamazaki@tohoku-mpu.ac.jp (H. Yamazaki).




Fig. 1. Structures of 1–25 isolated from aerial parts of *Lantana camara*.

the previously undescribed compounds (1–4) were elucidated based on their spectroscopic data, particularly 2D NMR spectral analyses (Fig. 2). Compound 5 has been reported as a semisynthetic derivative, and, therefore, this is the first study to show this compound as a natural product.

The EtOH extracts from three collection sites showed different phytochemical profiles with HPLC (Fig. 3).

In the present study, we describe the isolation, structural




Fig. 2. ¹H–¹H COSY and key HMBC correlations for 1.




Fig. 3. HPLC profiles of EtOH extracts from aerial parts of *Lantana camara* collected at Manado (A), Ishigaki Island (B), and Iriomote Island (C).

elucidation, phytochemical profiles, and biological activities of constituents from the aerial parts of *lantana* collected in Indonesia and Japan.

2. Results and discussion

2.1. Isolation of compounds 1–20 and 23–25 from the Indonesian *lantana*

The EtOH extract of *L. camara* collected at Manado, Indonesia, inhibited PTP1B activity (ca. 57% at 50 µg/mL) and was separated using an ODS column followed by repeated HPLC (ODS) to yield compounds **1** (15 mg), **2** (5.4 mg), **3** (1.7 mg), **4** (35 mg), **5** (1.0 mg), **6** (13 mg), **7** (11 mg), **8** (10 mg), **9** (1.5 mg), **10** (0.9 mg), **11** (1.9 mg), **12** (11 mg), **13** (20 mg), **14** (14 mg), **15** (45 mg), **16** (10 mg), **17** (1.0 mg), **18** (2.0 mg), **19** (1.6 mg), **20** (1.0 mg), **23** (3.2 mg), **24** (2.2 mg), and **25** (1.7 mg).

The structures of known compounds were identified as icterogenin (**6**) (Hart et al., 1976; Mahato and Kundu, 1994), 4-*epi*-hederagonic acid (**7**) (Hart et al., 1976; Wen et al., 2010), oleanolic acid (**8**) (Seebacher et al., 2003), 22β-oleanolic acid (**9**) (Tailor et al., 2013), 3β-hydroxy-lantadene A (**10**) (Kumar et al., 2013), 3β-hydroxy-lantadene B (**11**) (Kumar et al., 2013), 22-hydroxy-oleanonic acid (**12**) (Sharma and Sharma, 2006), lantadene B (**13**) (Barton et al., 1954; Mahato and Kundu, 1994), lantadene A (**14**) (Barton et al., 1956; Singh et al., 1999), oleanonic acid (**15**) (Wen et al., 2008), lantadene D (**16**) (Sharma et al., 1990), pomonic acid (**17**) (Cheng and Cao, 1992), pomolic acid (**18**) (Cheng and Cao, 1992), lantanilic acid (**19**) (Barre et al., 1997), camaric acid (**20**) (Barre et al., 1997), pectolarin (**23**) (Juang et al., 2005), hispidulin (**24**) (Juang et al., 2005), and pectolarigenin (**25**) (Juang et al., 2005) by comparing their spectroscopic data with those of reported values.

2.2. Structural elucidation of 1–5

The molecular formula of compound **1** was assigned as C₃₅H₅₂O₆ from FABMS (*m/z* 569.3846 [M + H]⁺, Δ +0.4 mmu) and NMR (Table 1). The ¹H and ¹³C NMR spectra of **1** (in CDCl₃) were very similar to those of lantadene B (**13**), except for the presence of an oxygenated methylene signal in **1** (δ_H 3.39 and 4.00, δ_C 65.7) instead of the methyl group at C-24 in **13** (δ_H 1.03, δ_C 21.5). The molecular weight (formula) of **1** was 16 Da (O) higher than that of **13**. Therefore, the structure of **1** was presumed to be a 24-hydroxy derivative of **13** and this was confirmed by COSY and HMBC data for **1** (Fig. 2). Hence, the planar structure of **1** was elucidated as 24-hydroxy-lantadene B (Fig. 1).

The relative configuration of **1** was elucidated as shown in Fig. 1 from the NOESY correlations between H-9 (δ 1.66)/H₃-27 (1.16), H-18 (3.03)/H₃-30 (0.99), H-21a (1.44)/H-22 (5.02), H-23 (0.86)/H-24b (4.00)/H₃-25 (0.92), and H₃-25/H₃-26 (0.82) (Table 1).

The ¹H and ¹³C NMR spectra of **2** resembled those of lantadene D (**16**). The molecular formula of **2** (C₃₄H₅₂O₆) deduced from HRFABMS (*m/z* 557.3843 [M + H]⁺, Δ +0.1 mmu) possessed one oxygen more than that of **16**. Comparisons of NMR data for **2** (Table 2) with those for **16** revealed the planar structure of **2** as 24-hydroxy-lantadene D (Fig. 1). The relative configuration of **2** was confirmed by the NOESY data for **2**, similar to that for **1** (Table 2 and Fig. 1).

Compound **3** had the molecular formula of C₃₅H₅₂O₆, which was deduced from HRFABMS (*m/z* 569.3840 [M + H]⁺, Δ -0.2 mmu) and NMR data (Table 3). The ¹H and ¹³C NMR spectra of **3** ascribable to the triterpene skeleton were similar to those of **1** and **2**. The marked differences observed in NMR data among **1**–**3** were the presence of a tigloyloxy group at C-22 in **3** (δ_H 6.78, 1.74, and 1.75; δ_C 166.7, 128.6, 137.8, 14.5, and 12.0) instead of the senecloyloxy and isobutyryloxy groups at C-22 in **1** and **2**, respectively. Thus, the planar structure of **3** was elucidated as 24-hydroxy-lantadene X (Fig. 1). Lantadene X was previously reported to be biotransformed from lantadene A (**14**) using the Gram-negative bacterium, *Alcaligenes*

Table 1
¹³C (100 MHz) and ¹H (400 MHz) NMR spectroscopic data for **1** (CDCl₃).

| Position | δ _C | δ _H mult. (J in Hz) | HMBC | NOESY |
|----------|----------------|--------------------------------------|------------------|---------|
| 1 | 38.5 | 1.55 m 1.91 m 2.38 m 2.57 m | 3, 10 10 | |
| 2 | 34.2 | — | — | — |
| 3 | 221.1 | — | — | — |
| 4 | 50.4 | 4 | — | — |
| 5 | 55.5 | 1.60 m | — | — |
| 6 | 19.1 | 1.29 m 1.52 m 1.30 m 1.48 m | 5 | — |
| 7 | 32.4 | — | — | — |
| 8 | 39.2 | — | — | — |
| 9 | 46.4 | 1.66 m | — | 27 |
| 10 | 36.5 | — | — | — |
| 11 | 23.7 | 1.94 m | 10 | — |
| 12 | 122.2 | 5.37 brs | 11, 13, 18 | — |
| 13 | 143.2 | — | — | — |
| 14 | 42.1 | — | — | — |
| 15 | 27.7 | 1.52 m | — | — |
| 16 | 24.0 | 1.88 m | 15, 17 | — |
| 17 | 50.5 | — | — | — |
| 18 | 38.7 | 3.03 dd (13.9, 3.9) | — | 30 |
| 19 | 46.0 | 1.29 m 1.68 m | 20 | — |
| 20 | 30.1 | — | — | — |
| 21 | 37.7 | 1.44 m 1.74 m | — | 22, 29 |
| 22 | 75.1 | 5.02 brs | 17, 18, 20 | 21a |
| 23 | 22.2 | 1.25 s | 3, 4, 5, 24 | — |
| 24 | 65.7 | 3.39 d (11.2) 4.00 d (11.2) | 3, 4, 5 3, 23 | 25 |
| 25 | 16.1 | 0.92 s | 1, 5, 9, 10 | 24b, 26 |
| 26 | 16.7 | 0.82 s | 7, 8, 9, 14 | 25 |
| 27 | 25.7 | 1.16 s | 8, 13, 14, 15 | 9 |
| 28 | 176.6 | — | — | — |
| 29 | 33.8 | 0.86 s | 19, 20, 21, 30 | 21a |
| 30 | 26.3 | 0.99 s | 19, 20, 21, 29 | 18 |
| 31 | 165.4 | — | — | — |
| 32 | 116.1 | 5.55 s | 31, 34, 35 | — |
| 33 | 157.1 | — | — | — |
| 34 | 20.2 | 2.12 s | 32, 33, 35 | — |
| 35 | 27.4 | 1.83 s | 32, 33, 34 | — |

faecalis (Singh et al., 1999). The relative configuration of **3** established by its NOESY spectrum was the same as those of **1** and **2** (Table 3 and Fig. 1).

Although the ¹H and ¹³C NMR spectra of **4** (Table 4) were similar to those of 4-*epi*-hederagonic acid (**7**), an oxygenated methine signal in **4** (δ_H 3.91, δ_C 74.3) was detected instead of the methylene signal at C-22 in **7**. The HRFABMS of **4** (*m/z* 487.3415 [M]⁺, Δ -0.8 mmu) gave the molecular formula of C₃₀H₄₆O₅, which possessed one oxygen more than that of **7**. Therefore, the planar structure of **4** was assigned as 22-hydroxy-4-*epi*-hederagonic acid (Fig. 1). The relative configuration of **4** was elucidated by an analysis of NOESY data for **4**, similar to those for **1**–**3** (Table 4 and Fig. 1).

The molecular formula of compound **5** was deduced as C₃₅H₅₆O₅ from FABMS (*m/z* 555.4031 [M - H]⁺, Δ -1.9 mmu) and NMR data (Table 5). The ¹H and ¹³C NMR spectra of **5** were similar to those of lantadene C (Johns et al., 1983), except for the presence of an oxygenated methine signal (δ_H 3.20, δ_C 79.0) in **5** instead of the carbonyl signal at the C-3 position in lantadene C. The planar structure of **5** was assigned as 3-hydroxy-lantadene C by an analysis of 1D and 2D NMR data for **5** (Table 5 and Fig. 1). The relative stereostructure of **5** was elucidated as 3β-hydroxy-lantadene C by NOESY data for **5** (Table 5 and Fig. 1). This structure was previously reported to be a semisynthetic derivative from lantadene C (Brown and Rimington, 1963). Therefore, this is the first study to report

Table 2
¹³C (100 MHz) and ¹H (400 MHz) NMR spectroscopic data for **2** (CDCl₃).

| Position | δ _c | δ _H (m) (J in Hz) | HMBC | NOESY |
|----------|----------------|--------------------------------------|----------------------|---------|
| 1 | 38.4 | 1.59 m 1.89 m | | |
| 2 | 34.1 | 2.37 m 2.56 m | 1, 3 | |
| 3 | 221.8 | — | | |
| 4 | 49.8 | — | | |
| 5 | 55.2 | 1.59 q | 4, 6, 10, 23 | |
| 6 | 19.1 | 1.29 m 1.52 m 1.31 m 1.50 m | 4 | |
| 7 | 32.3 | — | | |
| 8 | 39.1 | — | | |
| 9 | 46.3 | 1.68 m | | |
| 10 | 36.4 | — | | 27 |
| 11 | 23.6 | 1.92 m | 10 | |
| 12 | 122.1 | 5.38 brs | 9, 14, 18 | |
| 13 | 143.3 | — | | |
| 14 | 42.0 | — | | |
| 15 | 27.7 | 1.52 m | | |
| 16 | 24.0 | 1.86 m | 15, 17 | |
| 17 | 50.3 | — | | |
| 18 | 38.5 | 3.04 q (13.0 3.9) | | 30 |
| 19 | 46.0 | 1.31 m 1.67 m | | |
| 20 | 30.1 | — | | |
| 21 | 37.9 | 1.45 m 1.74 m | | 22, 29 |
| 22 | 75.6 | 5.00 brs | 18, 20 | 21a |
| 23 | 22.3 | 1.26 s | 3, 4, 5, 24 | |
| 24 | 65.6 | 3.37 d (11.1) 4.03 d (11.1) | 3, 4, 5, 23 3, 23 | 25 |
| 25 | 16.2 | 0.91 s | 1, 5, 9, 10 | 24b, 26 |
| 26 | 16.6 | 0.82 s | 7, 8, 9, 14 | 25 |
| 27 | 25.6 | 1.16 s | 8, 13, 14, 15 | 9 |
| 28 | 176.3 | — | | |
| 29 | 33.7 | 0.87 s | 19, 20, 21, 30 | 21a |
| 30 | 26.4 | 0.99 s | 19, 20, 21, 29 | 18 |
| 31 | 175.6 | — | | |
| 32 | 34.4 | 2.42 m | 31, 33, 34 | |
| 33 | 18.5 | 1.09 d (6.8) | 31, 32, 34 | |
| 34 | 19.1 | 1.08 d (6.8) | 31, 32, 33 | |

Table 3
¹³C (100 MHz) and ¹H (400 MHz) NMR spectroscopic data for **3** (CDCl₃).

| Position | δ _c | δ _H (m) (J in Hz) | HMBC | NOESY |
|----------|----------------|--------------------------------|----------------|---------|
| 1 | 37.7 | 1.57 m 1.87 m | | |
| 2 | 34.2 | 2.38 m 2.52 m | | |
| 3 | 221.1 | — | | |
| 4 | 50.4 | 4 | | |
| 5 | 55.5 | 1.60 m | | |
| 6 | 19.2 | 1.30 m 1.53 m | | |
| 7 | 32.3 | 1.30 m 1.49 m | | |
| 8 | 39.1 | — | | |
| 9 | 46.4 | 1.66 m | | 27 |
| 10 | 36.5 | — | | |
| 11 | 23.7 | 1.94 m | | |
| 12 | 122.3 | 5.41 brs | | |
| 13 | 142.9 | — | | |
| 14 | 42.1 | — | | |
| 15 | 27.7 | 1.53 m | | |
| 16 | 23.9 | 1.87 m | | |
| 17 | 50.5 | — | | |
| 18 | 38.6 | 3.09 q (10.1) | 17 | 30 |
| 19 | 46.0 | 1.32 m 1.66 m | | |
| 20 | 30.0 | — | | |
| 21 | 37.7 | 1.45 m 1.78 m | | 22, 29 |
| 22 | 76.1 | 5.03 brs | 18 | 21a |
| 23 | 22.2 | 1.25 s | 3, 4, 5, 24 | |
| 24 | 65.6 | 3.39 d (11.1) 4.00 d (11.1) | 3 3, 5, 23 | 25 |
| 25 | 16.1 | 0.92 s | 1, 5, 9, 10 | 24b, 26 |
| 26 | 16.6 | 0.82 s | 7, 8, 9, 14 | 25 |
| 27 | 25.7 | 1.16 s | 8, 13, 14, 15 | 9 |
| 28 | 176.0 | — | | |
| 29 | 33.7 | 0.87 s | 19, 20, 21, 30 | 21a |
| 30 | 26.1 | 0.97 s | 19, 20, 21, 29 | 18 |
| 31 | 166.7 | — | | |
| 32 | 128.6 | — | | |
| 33 | 137.8 | 6.78 q (6.8) | | |
| 34 | 14.5 | 1.74 d (6.8) | 32, 33 | |
| 35 | 12.0 | 1.75 s | 31, 32, 33 | |

compound **5** as a natural product. Since spectroscopic data and the configuration at C-3 were previously unknown, we described them herein.

The absolute configurations of oleanane triterpenes have been established by X-ray crystallographic analyses (Pattabhi et al., 1991; Nethaji et al., 1993). Since compounds **1–5** were obtained together with known derivatives from the same plant, these compounds appear to be biosynthesized via the same pathway. Therefore, the absolute configurations of **1–5** must be identical with those of the other components (**6–22**), which were supported by the same positive signs of specific rotations for **1–22**.

2.3. Phytochemical profiles of *lantana* from three collection sites

The EtOH extracts of *L. camara* collected at Ishigaki and Iriomote Islands (Okinawa, Japan) in 2016 inhibited PTP1B activity by 58 and 84%, respectively, at 50 μg/mL.

Fig. 3 shows the HPLC profiles of EtOH extracts from *lantana* collected at Manado (A), Ishigaki (B), and Iriomote (C). The peaks of 24-OH derivatives (**1–3**, **6**, and **7**) were detected in the Indonesian *lantana* only (Fig. 3A). The chromatogram of the Ishigaki *lantana* showed two major (**13** and **14**) and three minor peaks (**12**, **15**, and **16**). Two major peaks (**19** and **20**) were observed with five minor peaks (**13–15**, **21**, and **22**) in the chromatogram of the Iriomote *lantana*. Compounds **21** and **22** were isolated and identified as 22β-

tigloyloxylantanoic acid and lantanoic acid, respectively, by a comparison of spectroscopic data for **21** and **22** with those for reported values (Barre et al., 1997). Therefore, the Iriomote *lantana* mainly produced oleanane triterpenes with an ether bridge between C-3β and C-25. The same species of plant collected at three islands exhibited different phytochemical components. The enzymes oxidizing the C-24 and C-25 methyl groups will be involved in biosynthesis in the Indonesian and Iriomote species, respectively. On the other hand, the Ishigaki species may not have these enzymes.

2.4. Biological activity

The inhibitory effects of compounds **1–25** on PTP1B activity were evaluated using an enzyme assay according to a previously described method (Yamazaki et al., 2013). Oleanolic acid (**8**) exhibited the most potent activity with an IC₅₀ value of 2.0 μM (Table 6). This compound is used as a positive control in studies on PTP1B (Zhang et al., 2008), and commercial oleanolic acid hydrate showed an IC₅₀ value of 1.3 μM in the same bioassay. The inhibitory activities of compounds **7**, **8**, **15**, and **22** revealed that oxidation at C-3, hydroxylation at C-24, and the ether linkage between C-3 and C-25 were unfavorable for this activity.

The leaf and fruit extracts of *L. camara* have recently been

Table 4
¹³C (100 MHz) and ¹H (400 MHz) NMR spectroscopic data for **4** (CDCl₃).

| Position | δ _C | δ _H mult. (J in Hz) | HMBC | NOESY |
|----------|----------------|--------------------------------------|----------------|---------|
| 1 | 38.6 | 1.56 m 1.89 m | | |
| 2 | 34.3 | 2.40 m 2.52 m | 10 3 | |
| 3 | 220.8 | — | | |
| 4 | 50.8 | — | | |
| 5 | 55.6 | 1.54 m | 10 | |
| 6 | 19.2 | 1.30 m 1.52 m 1.33 m 1.48 m | | |
| 7 | 32.4 | — | 5 | |
| 8 | 39.2 | — | | |
| 9 | 46.5 | 1.67 m | | 27 |
| 10 | 36.5 | — | | |
| 11 | 23.8 | 1.93 m | | |
| 12 | 122.4 | 5.36 brs | | |
| 13 | 143.3 | — | | |
| 14 | 42.2 | — | | |
| 15 | 27.8 | 1.51 m | | |
| 16 | 24.3 | 1.86 m | 17 | |
| 17 | 52.3 | — | | |
| 18 | 38.2 | 3.00 m (14.0, 3.9) 1.23 m | 16 | 30 |
| 19 | 46.1 | 1.65 m | | |
| 20 | 30.2 | — | | |
| 21 | 41.3 | 1.48 m 1.70 m | | 22, 29 |
| 22 | 74.3 | 3.91 brs | 20 | 21a |
| 23 | 22.2 | 1.25 s | 3, 4, 5, 24 | |
| 24 | 65.8 | 3.44 d (11.1) 3.96 d (11.1) | 3, 4 23 | 25 |
| 25 | 16.1 | 0.94 s | 1, 5, 9, 10 | 24b, 26 |
| 26 | 16.7 | 0.81 s | 7, 8, 9, 14 | 25 |
| 27 | 25.6 | 1.14 s | 8, 13, 14, 15 | 9 |
| 28 | 178.5 | — | | |
| 29 | 33.9 | 0.88 s | 19, 20, 21, 30 | 21a |
| 30 | 27.1 | 1.10 s | 19, 20, 21, 29 | 18 |

reported to improve blood glucose levels, HbA1c profiles, and body weights (Govindappa, 2015). Consequently, the relationship between anti-diabetic properties and PTP1B inhibition will be of interest in future studies on clinical applications of the plant for the treatment of type 2 diabetes.

3. Conclusions

The aerial parts of *L. camara* L. (lantana) were collected in Indonesia (Manado) and Japan (Ishigaki and Iriomote Islands, Okinawa), and the phytochemical study gave four previously undescribed oleanane triterpenes (**1–4**) together with 21 known constituents (**5–25**). The Indonesian lantana contained the most diverse components. Since plants grown in tropical regions are generally exposed to severe environments, such as UV, microorganisms, and insects, a wide variety of chemical components will be produced to defend against these insults. Most of the isolated compounds exhibited PTP1B inhibitory activity, suggesting that *L. camara* has potential as a prospective drug for type 2 diabetes and obesity with a new therapeutic approach.

4. Experimental

4.1. General experimental procedure

FABMS was performed using MS-MS 700 mass spectrometer (JEOL, Tokyo, Japan). ¹H and ¹³C NMR spectra were recorded on a JNM-AL-400 NMR spectrometer (JEOL) at 400 MHz for ¹H and 100 MHz for ¹³C in CDCl₃ (δ_H 7.24, δ_C 77.0). Optical rotations were

Table 5
¹³C (100 MHz) and ¹H (400 MHz) NMR spectroscopic data for **5** (CDCl₃).

| Position | δ _C | δ _H mult. (J in Hz) | HMBC | NOESY |
|----------|----------------|--------------------------------------|----------------|--------|
| 1 | 38.5 | 1.54 m 1.78 m | 3 | |
| 2 | 27.2 | 1.50 m 1.59 m | | |
| 3 | 79.0 | 3.20 dd (11.3, 4.4) | | 23 |
| 4 | 39.2 | — | | |
| 5 | 55.2 | 0.73 d (12.0) | | 9 |
| 6 | 18.3 | 1.28 m 1.54 m 1.26 m 1.45 m | | |
| 7 | 32.7 | — | 28 | |
| 8 | 38.5 | — | | |
| 9 | 47.6 | 1.57 m | | 5, 27 |
| 10 | 37.0 | — | | |
| 11 | 23.4 | 1.93 m | | |
| 12 | 122.8 | 5.38 brs | | |
| 13 | 142.9 | — | | |
| 14 | 42.0 | — | | |
| 15 | 27.7 | 1.48 m | | |
| 16 | 24.1 | 1.88 m | | |
| 17 | 50.4 | — | | |
| 18 | 38.5 | 3.02 d (12.7) 1.28 m | | 30 |
| 19 | 45.9 | 1.28 m 1.71 m | | |
| 20 | 30.0 | — | | |
| 21 | 38.0 | 1.45 m 1.74 m | | 22, 29 |
| 22 | 75.6 | 5.03 brs | | 21a |
| 23 | 28.1 | 0.77 s | 3, 4, 5, 24 | 3 |
| 24 | 15.6 | 0.97 s | 3, 4, 5, 23 | 25 |
| 25 | 15.4 | 0.90 s | 1, 5, 9, 10 | 24, 26 |
| 26 | 16.8 | 0.78 s | 7, 8, 9, 14 | 25 |
| 27 | 25.9 | 1.15 s | 8, 13, 14, 15 | 9 |
| 28 | 178.4 | — | | |
| 29 | 33.7 | 0.88 s | 19, 20, 21, 30 | 21a |
| 30 | 26.6 | 1.01 s | 19, 20, 21, 29 | 18 |
| 31 | 175.2 | — | | |
| 32 | 41.6 | 2.25 brq (6.8) | | |
| 33 | 26.2 | 1.37 m | | |
| 34 | 11.8 | 0.85 t (7.6) | 32, 33 | |
| 35 | 16.6 | 1.07 d (6.8) | 31, 32, 33 | |

Table 6
 Effects of **1–25** on protein tyrosine phosphatase 1B activity.

| Compound | PTP1B (IC ₅₀ , μM) |
|-----------------------------|-------------------------------|
| 1 | 7.3 |
| 2 | >18 |
| 3 | >18 |
| 4 | >21 |
| 5 | 7.3 |
| 6 | 11 |
| 7 | 8.1 |
| 8 | 2.0 |
| 9 | 7.9 |
| 10 | 7.2 |
| 11 | 5.1 |
| 12 | 6.9 |
| 13 | 5.5 |
| 14 | 5.2 |
| 15 | 6.9 |
| 16 | 7.9 |
| 17 | 10.5 |
| 18 | 10.6 |
| 19 | 7.5 |
| 20 | 5.1 |
| 21 | >18 |
| 22 | 13 |
| 23 | >16 |
| 24 | >33 |
| 25 | 36% inhibition at 32 μM |
| Oleanolic acid ^a | 1.3 |

^a Positive control.

measured with a **8** JASCO P-2300 digital polarimeter (JASCO, Ltd., Tokyo, Japan). UV spectra were obtained on a Hitachi U-3310 UV–Visible spectrophotometer (Hitachi, Ltd., Tokyo, Japan) and IR spectra on a PerkinElmer Spectrum One Fourier transform infrared spectrometer (Waltham, MA, USA). Preparative HPLC was performed using the L-6200 system (Hitachi Ltd.).

4.2. Materials

PTP1B was purchased from **54** Enzo Life Sciences (Farmingdale, NY, USA). *p*-Nitrophenyl phosphate (pNPP) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Oleanolic acid hydrate was purchased from Tokyo Chemical Industry (Tokyo, Japan). Plastic plates (96-well) were purchased from **25** Corning Inc. (Corning, NY, USA). All other chemicals including organic solvents were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan).

4.3. Isolation of compounds 1–25

19 The aerial parts of *Lantana camara* L. (family Verbenaceae) were collected at Manado in North Sulawesi (Indonesia) at GPS coordinates (N1°15'7.2", E124°51'21.6") and Ishigaki and Iriomote Islands in Okinawa (Japan) at GPS coordinates (N24°22'55.2", E124°10'33.6" and N24°21'14.9", E123°56'14.4", respectively) in 2016. The plants were identified by Mr. Mamoru Yamada (Banna Park, **7** Dkinawa, Japan). Voucher specimens have been deposited at the Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University as 16-2-27 = LAN-S (Manado), 16-9-4 = P2-2 (Ishigaki Island), and 16-9-8 = P3-2 (Iriomote Island).

The Indonesian lantana (16-2-27 = LAN-S) (1.0 kg, wet weight) was extracted with EtOH (1.0 L × 3) at room temperature and evaporated to give a crude extract (21 g). A portion (10 g) of the extract was separated by an ODS column (100 g) with the stepwise elution of CH₃OH in H₂O into seven fractions (Frs. 1–7).

Fr. 6 (891 mg, eluted with 100% CH₃OH) was subjected to preparative HPLC [column, PEGASIL ODS (Senshu Sci. Co. Ltd., Tokyo, Japan), i.d. 10 mm × 250 mm; solvent, 88% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm] to give **1** (15 mg), **6** (13 mg), **7** (11 mg), **12** (11 mg), **13** (20 mg), **14** (14 mg), **15** (45 mg), **16** (10 mg), and **11** (1.9 mg), and four subfractions (Frs. 6-1–6-4). Compounds **4** (1.8 mg), **1** (**12**, 0 mg), and **18** (2.0 mg) were obtained from Fr. 6-1 (29 mg) by preparative HPLC (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 77% **38** OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm). Fr. 6-2 (38 mg) was purified by repeated HPLC (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 81% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm) to yield **2** (5.4 mg), **3** (1.7 mg), and **9** (1.5 mg). Compounds **19** (1.6 mg) and **10** (0.9 mg) were isolated from Fr. 6-3 (9.5 mg) using preparative HPLC (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 80% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm). Compounds **20** (1.0 mg), **5** (1.0 mg), and **8** (10 mg) were obtained from Fr. 6-4 (20 mg) by preparative HPLC (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 86% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm). Fr. 4 (110 mg, eluted with 70% CH₃OH) was subjected to HPLC separation (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 63% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm) to afford **23** (3.2 mg), **24** (2.2 mg), and **25** (1.7 mg).

The aerial parts of *L. camara* (182 g, wet weight) collected at Iriomote Island (16-9-8 = P3-2) were extracted three times with EtOH (1.0 L) at room temperature, and the extract was evaporated (3.8 g). A portion (250 mg) of the extract was purified by HPLC (column, PEGASIL ODS, i.d. 10 mm × 250 mm; solvent, 88% CH₃OH in H₂O; flow rate, 2.0 mL/min; detection, UV at 210 nm) to give **19**

(4.8 mg), **20** (7.7 mg), **21** (0.4 mg), and **22** (0.9 mg).

4.3.1. 24-Hydroxy-lantadene B (1)

Yellow solids; $[\alpha]_D^{22} +50.5$ (c 0.20, CH₃OH); IR (KBr) **48** 3446, 2948, 2343, 1717, 1459, 1381, 1229, 1140, 1073, 1037, 852 cm⁻¹; UV (CH₃OH) λ_{\max} nm (log ϵ) 210 (4.4); FABMS *m/z* 569 [M + H]⁺; HRFABMS *m/z* 569.3846 ([M + H]⁺, calcd for C₃₅H₅₃O₆, 569.3842); ¹H and ¹³C NMR (CDCl₃) data, see Table 1.

4.3.2. 24-Hydroxy-lantadene D (2)

Colorless solids; $[\alpha]_D^{22} +57.4$ (c 0.20, CH₃OH); IR (KBr) ν_{\max} 3448, 2952, 2347, 1733, 1698, 1459, 1388, 1259, 1189, 1147, 1034, 814 cm⁻¹; UV (CH₃OH) λ_{\max} nm (log ϵ) 202 (4.2); FABMS *m/z* 557 [M + H]⁺; **24** FABMS *m/z* 557.3843 ([M + H]⁺, calcd for C₃₄H₅₃O₆, 557.3842); ¹H and ¹³C NMR (CDCl₃) data, see Table 2.

4.3.3. 24-Hydroxy-lantadene X (3)

Colorless solids; $[\alpha]_D^{22} +39.2$ (c 0.20, CH₃OH); IR (KBr) ν_{\max} 3422, 2948, 2361, 1716, 1459, 1385, 1267, 1135, 1036, 805 cm⁻¹; UV (CH₃OH) λ_{\max} nm (log ϵ) 201 (4.3); FABMS *m/z* 569 [M + H]⁺; **24** FABMS *m/z* 569.3840 ([M + H]⁺, calcd for C₃₅H₅₃O₆, 569.3842); ¹H and ¹³C NMR (CDCl₃) data, see Table 3.

4.3.4. 22-Hydroxy-4-epi-hederagonic acid (4)

Colorless solids; $[\alpha]_D^{22} +36.5$ (c 0.20, CH₃OH); IR (KBr) ν_{\max} 3447, 2947, 2362, 1705, 1459, 1387, 12**53**, 1188, 1036, 802 cm⁻¹; UV (CH₃OH) λ_{\max} nm (log ϵ) 202 (4.0); FABMS *m/z* 487 [M + H]⁺; HRFABMS *m/z* 487.3415 ([M + H]⁺, calcd for C₃₀H₄₇O₅, 487.3423); ¹H and ¹³C NMR (CDCl₃) data, see Table 4.

4.3.5. 3 β -Hydroxy-lantadene C (5)

Colorless solids; $[\alpha]_D^{22} +43.1$ (c 0.05, CH₃OH); IR (KBr) ν_{\max} 3447, 2946, 2362, 1690, 1459, 1386, 1261, 1208, 1188, 1140, 1030, 804 cm⁻¹; UV (CH₃OH) λ_{\max} nm (log ϵ) 202 (3.0); FABMS *m/z* 555 [M – H]⁻; HRFABMS *m/z* 555.4031 ([M – H]⁻, calcd for C₃₅H₅₅O₅, 555.4050); ¹H and ¹³C NMR (CDCl₃) data, see Table 5.

4.4. PTP1B inhibitory assay

PTP1B inhibitory activity was assessed by measuring the rate of hydrolysis of a substrate, pNPP, according to the previously described method with a slight modification **21** (Cui et al., 2006; Yamazaki et al., 2013). PTP1B (100 μ L of 0.5 μ g/mL stock solution) in 50 mM citrate buffer (pH 6.0) containing 0.1 M NaCl, 1 mM dithiothreitol (DTT), and 1 mM *N,N,N',N'*-ethylenediamine tetraacetate (EDTA) was added to each well of a 96-well plastic plate. A sample (2.0 μ L in **15** H) was added to each well to make the final concentration and incubated at 37 °C for 10 min. The reaction was **37** initiated by the addition of pNPP in the citrate buffer (100 μ L of 4.0 mM stock solution), incubated at 37 °C for 30 min, and terminated using 10 μ L of a stop solution (10 M NaOH). The optical density of each well was measured at 405 nm using an MTP-500 microplate reader (Corona Electric Co., Ltd., Ibaraki, Japan). PTP1B inhibitory activity (%) was defined as $[1 - (\text{ABS}_{\text{sample}} - \text{ABS}_{\text{blank}}) / (\text{ABS}_{\text{control}} - \text{ABS}_{\text{blank}})] \times 100$. ABS_{blank} is the absorbance of wells containing only the buffer and pNPP. ABS_{control} is the absorbance of *p*-nitrophenol liberated by the enzyme in the assay system without a test sample, whereas ABS_{sample} is that with a test sample. Assays were performed in two independent experiments for all test samples. **5** Oleanolic acid, a known phosphatase inhibitor (Zhang et al., 2008), was used as a positive control. Data are expressed as the average of three independent experiments performed in duplicate.

Acknowledgments

This work was supported in part by the Kanagawa Foundation for the Promotion of Medical Science to H. Y. and a Grant for Basic Science Research Projects from The Sumitomo Foundation to H. Y. We express our thanks to Mr. T. Matsuki and S. Sato of Tohoku Medical and Pharmaceutical University for measuring mass spectra and to Mr. M. Yamada of Banna Park (Okinawa, Japan) for identifying the plants.

References

- Abdjul, D.B., Yamazaki, H., Takahashi, O., Kirikoshi, R., Ukai, K., Namikoshi, M., 2016. Sesquiterpene hydroquinones with protein tyrosine phosphatase 1B inhibitory activities from a *Dysidea* sp. marine sponge collected in Okinawa. *J. Nat. Prod.* 79, 1842–1847.
- Barre, J.T., Bowden, B.F., Coll, J.C., De Jesus, J., De La Fuente, V.E., Janairo, G.C., Ragasa, C.Y., 1997. A bioactive triterpene from *Lantana camara*. *Phytochemistry* 45, 321–324.
- Barton, D.H.R., De Mayo, P., Warnhoff, E.W., Jeger, O., Perold, G.W., 1954. Triterpenoid. Part XIX. The constitution of lantadene B. *J. Chem. Soc.* 3689–3692.
- Barton, D.H.R., De Mayo, P., Orr, J.C., 1956. Triterpenoid. Part XXIII. The nature of lantadene A. *J. Chem. Soc.* 4160–4162.
- Brown, J.M., Rimington, C., 1963. Studies on biliary excretion in the rabbit. II. The relationship between the chemical structure of certain natural or synthetic pentacyclic triterpenes and their icterogenic activity. Part 2: the substituents on carbon atoms 17, 19, 20 and 22. *Proc. R. Soc. Lond. B Biol. Sci.* 28, 246–257.
- Cheng, D.L., Cao, X.P., 1992. Pomolic acid derivatives from the root of *Sanguisorba officinalis*. *Phytochemistry* 31, 1317–1320.
- Cui, L., Na, M.K., Oh, H., Bae, E.Y., Jeong, D.G., Ryu, S.E., Kim, S., Kim, B.Y., Oh, W.K., Ahn, J.S., 2006. Protein tyrosine phosphatase 1B inhibitors from *Morus* root bark. *Bioorg. Med. Chem. Lett.* 16, 1426–1429.
- Ghisalberti, E.L., 2000. *Lantana camara* L. (Verbenaceae). *Fitoterapia* 71, 467–486.
- Govindappa, M., 2015. A review on role of plant(s) extracts and its phytochemicals for the management of diabetes. *J. Diabetes Metab.* 6, 1000565.
- Hart, N.K., Lambertson, J.A., Sioumis, A.A., Soares, H., 1976. New triterpenes of *Lantana camara*. A comparative study of the constituents of several taxa. *Aust. J. Chem.* 29, 655–671.
- Johns, S.R., Lambertson, J.A., Morton, T.C., Soares, H., Willing, R.I., 1983. 22 β -(S)-2-Methylbutanoyloxy]-3-oxoolean-12-en-28-oic acid, a new constituent of *Lantana camara*. *Aust. J. Chem.* 36, 1895–1902.
- Juang, F.C., Chen, Y.F., Lin, F.M., Huang, K.F., 2005. Constituents from the leaves of *Lantana camara* (IV). *J. Chin. Med.* 16, 149–155.
- Kumar, S.S., Tailor, N., Lee, H.B., Sharma, M., 2013. Reduced lantadenes A and B: semi-synthetic synthesis, selective cytotoxicity, apoptosis induction and inhibition of NO, TNF- α production in HL-60 cells. *Med. Chem. Res.* 22, 3379–3388.
- Maarisit, W., Yamazaki, H., Kanno, S., Tomizawa, A., Rotinsulu, H., Wewengkang, D.S., Sumilat, D.A., Ukai, K., Kapojos, M.M., Namikoshi, M., 2017. A tetramic acid derivative with protein tyrosine phosphatase 1B inhibitory activity and a new nortriterpene glycoside from the Indonesian marine sponge *Petrosia* sp. *Bioorg. Med. Chem. Lett.* 27, 999–1002.
- Mahato, S.B., Kundu, A.P., 1994. ¹³C NMR spectra of pentacyclic triterpenoids: a compilation and some salient features. *Phytochemistry* 37, 1517–1575.
- Maheswari, N., Karthikeyan, C., Trivedi, P., Moorthy, N.S., 2017. Recent advances in protein tyrosine phosphatase 1B targeted drug discovery for type II diabetes and obesity. *Curr. Drug Targets.* <http://dx.doi.org/10.2174/1389450118666170222143739>.
- Nethaji, M., Rufes, C., Sadasivan, C., Pattabhi, Vasantha, Sharma, O.P., 1993. Molecular structure of lantadene-B&C, triterpenoids of *Lantana camara*, red variety: lantadene-B, 22 β -angeloyloxy-3-oxoolean-12-en-28-oic acid; Lantadene-C, 22 β -(S)-2'-methyl butanoyloxy-3-oxoolean-12-en-28-oic acid. *J. Cryst. Spectro Res.* 23, 469–472.
- Pattabhi, V., Sukumar, N., Sharma, O.P., 1991. Structure of lantadene A, the major triterpenoid of *Lantana camara*, red variety. *Acta Cryst.* C47, 810–812.
- Seebacher, W., Simic, N., Weis, R., Saf, R., Kunert, O., 2003. Complete assignments of ¹H and ¹³C NMR resonance of oleanolic acid, 18 α -oleanolic acid, ursolic acid and their 11-oxo derivatives. *Magn. Reson. Chem.* 41, 636–638.
- Sharma, O.P., Dawra, R.K., Ramesh, D., 1990. A triterpenoid acid, lantadene D from *Lantana camara* var. *aculeata*. *Phytochemistry* 29, 3961–3962.
- Sharma, N., Sharma, P.D., 2006. Optimization of lantadenes isolation and preparation of 22 β -hydroxyoleanonic acid. *Chem. Nat. Prod.* 42, 442–444.
- Singh, A., Sharma, O.P., Dawra, R.K., Kanwar, S.S., Mahato, S.B., 1999. Biotransformation of lantadene A (22 β -angeloyloxy-3-oxoolean-12-en-28-oic-acid), the pentacyclic triterpenoid, by *Alcaligenes faecalis*. *Biodegradation* 10, 373–381.
- Sumilat, D.A., Yamazaki, H., Kanno, S., Saito, R., Watanabe, Y., Namikoshi, M., 2017. Biphenyl ether derivatives with protein tyrosine phosphatase 1B inhibitory activity from the freshwater fungus *Phoma* sp. *J. Antibiot.* 70, 331–333.
- Tailor, N.K., Boon, H.L., Sharma, M., 2013. Synthesis and *in vitro* anticancer studies of novel C-2 arylidene congeners of lantadenes. *Eur. J. Med. Chem.* 64, 285–291.
- Wang, L.J., Jiang, B., Wu, N., Wang, S.Y., Shi, D.Y., 2015. Natural and semisynthetic protein tyrosine phosphatase 1B (PTP1B) inhibitors as anti-diabetic agents. *RSC Adv.* 5, 48822–48834.
- Wen, X.A., Sun, H., Liu, J., Cheng, K., Zhang, P., Zhang, L., Hao, J., Zhang, L., Ni, P., Zographos, S.E., Leonidas, D.D., Alexacou, K.M., Gimisis, T., Hayes, J.M., Oikonomakos, N.G., 2008. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies. *J. Med. Chem.* 51, 3540–3554.
- Wen, X.A., Liu, J., Zhang, L.Y., Ni, P.Z., Sun, H.B., 2010. Synthesis and biological evaluation of arjunolic acid, bayogenin, hederagonic acid and 4-*epi*-hederagonic acid as glycogen phosphorylase inhibitors. *Chin. J. Nat. Med.* 8, 441–448.
- Yamazaki, H., Sumilat, D.A., Kanno, S., Ukai, K., Rotinsulu, H., Wewengkang, D.S., Ishikawa, M., Mangindaan, R.E.P., Namikoshi, M., 2013. A polybromodiphenyl ether from an Indonesian marine sponge *Lamellodysidea herbacea* and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment. *J. Nat. Med.* 67, 730–735.
- Yamazaki, H., Ukai, K., Namikoshi, M., 2016. Asperdichrome, an unusual dimer of tetrahydroxanthone through an ether bond, with protein tyrosine phosphatase 1B inhibitory activity, from the Okinawan freshwater *Aspergillus* sp. TPU1343. *Tetrahedron Lett.* 57, 732–735.
- Zhang, S., Zhang, Z.Y., 2007. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. *Drug Discov. Today* 12, 373–381.
- Zhang, Y.N., Zhang, W., Hong, D., Shi, L., Shen, Q., Li, J.-Y., Li, J., Hu, L.-H., 2008. Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities. *Bioorg. Med. Chem.* 16, 8697–8705.

Oleanane triterpenes with protein tyrosine phosphatase 1B inhibitory activity from aerial parts of Lantana camara collected in Indonesia and Japan

ORIGINALITY REPORT

15%

SIMILARITY INDEX

8%

INTERNET SOURCES

13%

PUBLICATIONS

7%

STUDENT PAPERS

PRIMARY SOURCES

- 1 Wang, Han, Qi Wang, Su-Long Xiao, Fei Yu, Min Ye, Yong-Xiang Zheng, Chuan-Ke Zhao, Di-An Sun, Li-He Zhang, and De-Min Zhou. "Elucidation of the pharmacophore of echinocystic acid, a new lead for blocking HCV entry", *European Journal of Medicinal Chemistry*, 2013.
Publication 1%
- 2 pesquisa.bvsalud.org
Internet Source 1%
- 3 Vincent Dumontet, Odile Thoison, Olamrewaju R. Omobuwajo, Marie-Thérèse Martin et al. "New nitrogenous and aromatic derivatives from *Aglaia argentea* and *A. forbesii*", *Tetrahedron*, 1996
Publication 1%
- 4 Elsayed, Heba E., Mohamed R. Akl, Hassan Y. Ebrahim, Asmaa A. Sallam, Eman G. Haggag, Amel M. Kamal, and El Sayed Khalid A. 1%

"Discovery, Optimization and Pharmacophore Modeling of Oleanolic Acid and Analogues as Breast Cancer Cell Migration and Invasion Inhibitors Through Targeting Brk/Paxillin/Rac1 axis", Chemical Biology & Drug Design, 2014.

Publication

5

repository.up.ac.za

Internet Source

1%

6

Masaki Gushiken, Ippei Kagiya, Hikaru Kato, Toshiyuki Kuwana et al. "Manadodioxans A-E: polyketide endoperoxides from the marine sponge *Plakortis bergquistae*", Journal of Natural Medicines, 2015

Publication

<1%

7

pubsdc3.acs.org

Internet Source

<1%

8

Xue-Mei Hou, Yue-Ying Li, Yun-Wei Shi, Yao-Wei Fang, Rong Chao, Yu-Cheng Gu, Chang-Yun Wang, Chang-Lun Shao. " Integrating Molecular Networking and H NMR To Target the Isolation of Chrysogeamides from a Library of Marine-Derived Fungi ", The Journal of Organic Chemistry, 2019

Publication

<1%

9

Submitted to Western Governors University

Student Paper

<1%

10 Tsukamoto, S.. "Aptamine, an alkaloid from the sponge *Aaptos suberitoides*, functions as a proteasome inhibitor", *Bioorganic & Medicinal Chemistry Letters*, 20100601

Publication

<1%

11 Submitted to Chonnam National University

Student Paper

<1%

12 "Structure-activity Relationships of Stemphones, Potentiators of Imipenem Activity against Methicillin-resistant *Staphylococcus aureus*", *The Journal of Antibiotics*, 07/2008

Publication

<1%

13 self-medication.pha.nihon-u.ac.jp

Internet Source

<1%

14 Submitted to Indian Institute of Information Technology, Allahabad

Student Paper

<1%

15 www.spandidos-publications.com

Internet Source

<1%

16 Submitted to University of New England

Student Paper

<1%

17 Suga, A.. "Two lignan dimers from bamboo stems (*Phyllostachys edulis*)", *Phytochemistry*, 200311

Publication

<1%

| | | |
|----|---|-----|
| 18 | "Graphical Contents List", <i>Phytochemistry</i> , 2017 Publication | <1% |
| 19 | Sabira Begum. "Noroleanane Triterpenoids from the Aerial Parts of <i>Lantana camara</i> ", <i>Helvetica Chimica Acta</i> , 03/2008 Publication | <1% |
| 20 | Kyeong Wan Woo, Joon Min Cha, Sang Un Choi, Kang Ro Lee. "A new triterpene glycoside from the stems of <i>Lagerstroemia indica</i> ", <i>Archives of Pharmacal Research</i> , 2016 Publication | <1% |
| 21 | tobias-lib.uni-tuebingen.de Internet Source | <1% |
| 22 | www.jove.com Internet Source | <1% |
| 23 | preview-zoologicalletters.biomedcentral.com Internet Source | <1% |
| 24 | Submitted to University of Science and Technology Student Paper | <1% |
| 25 | Liu, J.. "The anti-androgen effect of ganoderol B isolated from the fruiting body of <i>Ganoderma lucidum</i> ", <i>Bioorganic & Medicinal Chemistry</i> , 20070715 Publication | <1% |

26 Wen-Chen Chen, Jyh-Horng Sheu, Lee-Shing Fang, Wan-Ping Hu, Ping-Jyun Sung. "3 α ,7 α ,12 α -Triacetoxo-5 β -cholanic acid, a steroid from the Formosan soft coral sp. (Alcyoniidae)", *Natural Product Research*, 2006
Publication

<1%

27 www.mdpi.com
Internet Source

<1%

28 Sunil K. Chattopadhyay, Gour C. Saha, Ram P. Sharma, Sushil Kumar, Raja Roy. "A rearranged taxane from the himalayan yew *Taxus wallichiana*", *Phytochemistry*, 1996
Publication

<1%

29 Submitted to October University for Modern Sciences and Arts (MSA)
Student Paper

<1%

30 f1000.com
Internet Source

<1%

31 Wonsik Jeong. "Bioactive triterpenoids from *Callistemon lanceolatus*", *Archives of Pharmacal Research*, 06/2009
Publication

<1%

32 Nesma M. Mohamed, Makboul A. Makboul, Salwa F. Farag, Surendra Jain, Melissa R. Jacob, Babu L. Tekwani, Samir A. Ross. "Triterpenes from the roots of *Lantana*

<1%

montevidensis with antiprotozoal activity",
Phytochemistry Letters, 2016

Publication

33

"Plant and Human Health, Volume 1", Springer
Science and Business Media LLC, 2018

Publication

34

Hui-Zheng Fu, Yong-Ming Luo, Chuang-Jun Li,
Jing-Zhi Yang, Dong-Ming Zhang. " Psidials
A–C, Three Unusual Meroterpenoids from the
Leaves of L ", Organic Letters, 2010

Publication

35

Hui Yang. "Constituents of *Salvia trijuga*",
Pharmaceutical Biology (Formerly International
Journal of Pharmacognosy), 8/1/2003

Publication

36

ecc.isc.gov.ir

Internet Source

37

www.cuprumplant.com

Internet Source

38

Liuhong Zhang, Shah Niaz, Dilfaraz Khan, Zhen
Wang, Yonghong Zhu, Haiyun Zhou,
Yongcheng Lin, Jing Li, Lan Liu. "Induction of
Diverse Bioactive Secondary Metabolites from
the Mangrove Endophytic Fungus *Trichoderma*
sp. (Strain 307) by Co-Cultivation with
Acinetobacter johnsonii (Strain B2)", Marine
Drugs, 2017

<1%

<1%

<1%

<1%

<1%

<1%

39

www.recentmedicalfindings.com

Internet Source

<1%

40

Cheng-Shi Jiang, Werner E. G. Müller, Heinz C. Schröder, Yue-Wei Guo. "Disulfide- and Multisulfide-Containing Metabolites from Marine Organisms", Chemical Reviews, 2011

Publication

<1%

41

calraisins.org

Internet Source

<1%

42

ir.kagoshima-u.ac.jp

Internet Source

<1%

43

Lin, Chao, Xiaoan Wen, and Hongbin Sun. "Oleanolic acid derivatives for pharmaceutical use: a patent review", Expert Opinion on Therapeutic Patents, 2016.

Publication

<1%

44

Yamazaki, H.. "The 1.2 GeV photon tagging system at LNS-Tohoku", Nuclear Inst. and Methods in Physics Research, A, 20050101

Publication

<1%

45

Amna Parveen, Mirim Jin, Sun Yeou Kim. "Bioactive phytochemicals that regulate the cellular processes involved in diabetic nephropathy", Phytomedicine, 2018

Publication

<1%

46

www.dierk-raabe.com

Internet Source

<1%

47

Submitted to Chang Gung University

Student Paper

<1%

48

Pedras, M.S.C.. "Design, synthesis, and evaluation of potential inhibitors of brassinin glucosyltransferase, a phytoalexin detoxifying enzyme from *Sclerotinia sclerotiorum*", *Bioorganic & Medicinal Chemistry*, 20070901

Publication

<1%

49

citeseerx.ist.psu.edu

Internet Source

<1%

50

Nagaraju Kerru, Ashona Singh-Pillay, Paul Awolade, Parvesh Singh. "Current anti-diabetic agents and their molecular targets: A review", *European Journal of Medicinal Chemistry*, 2018

Publication

<1%

51

Submitted to Chulalongkorn University

Student Paper

<1%

52

Submitted to Higher Education Commission
Pakistan

Student Paper

<1%

53

Toshiro Konoike, Kazuhiro Takahashi, Yoji Kitaura, Yasuhiko Kanda. "Synthesis of [2-¹³C]-oleanolic acid and [2-¹³C]-myricerone", *Tetrahedron*, 1999

<1%

54

Submitted to Queen Mary and Westfield College

Student Paper

<1%

55

Renata Diniz. "A new triterpene of *Miconia macrothyrsa* leaves: 28-carboxy-3-oxoolean-12-en-21±-yl acetate", Acta Crystallographica Section E Structure Reports Online, 10/11/2006

Publication

<1%

56

Sousa, Erlânio O., and José G.M. Costa. "Genus Lantana: chemical aspects and biological activities", Revista Brasileira de Farmacognosia, 2012.

Publication

<1%

Exclude quotes On

Exclude matches Off

Exclude bibliography On